Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2017-07-31
Target enrollment:
Participant gender:
Summary
This study will examine biomarkers involved in osteomimicry in bone metastases and
circulating tumor cells (CTCs) of men with mCRPC before and during therapy with the
bone-targeting radiopharmaceutical radium-223. This study will also examine the
bio-distribution of radium-223 in bone and bone metastases of men with mCRPC.
The investigators hypothesize that bone metastases and CTCs in men with mCRPC will commonly
express markers of EMT/plasticity and osteomimicry, not just in the normal surrounding
osteoblastic stroma but in the epithelial tumor cells themselves and that radium-223 will
target both of these compartments including the more mesenchymal/osteoblastic tumor cells and
the surrounding osteoblasts in the active bone microenvironment, with a relative sparing of
normal bone and bone marrow.